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ABSTRACT An efficient test system for serine/threonine protein kinase inhibitors screening has been developed based 
on the E. coli protein system APHVIII/Pk25. Phosphorylation of aminoglycoside phosphotransferase VIII (APHVIII) 
by protein kinases enhances resistance of the bacterial cell to aminoglycoside antibiotics, e.g. kanamycin. Addition 
of protein kinase inhibitors prevents phosphorylation and increases cell sensitivity to kanamycin. We have obtained 
modifications of APHVIII in which phosphorylatable Ser146 was encompassed into the canonical autophosphorylation 
sequence of Streptomyces coelicolor Pk25 protein kinase. Mutant and wild-type aphVIII were cloned into E. coli with 
the catalytic domain of pk25. As a result of the expression of these genes, accumulation of corresponding proteins was 
clearly observed. Extracted from bacterial lysates, Pk25 demonstrated its ability to autophosphorylate. It was shown 
that variants of E. coli containing both aphVIII and рк25 were more resistant to kanamycin than those carrying only 
aphVIII. Protein kinase inhibitors of the indolylmaleimide class actively inhibited Pk25 and reduced cell resistance 
to kanamycin. Modeling of APHVIII and Pk25 3D structures showed that pSer146 is an analog of phosphoserine in 
the ribose pocket of protein kinase A. Pk25 conformation was similar to that of РknB of Mycobacterium tuberculosis. 
Potential indolylmaleimide inhibitors were docked into the ATP-binding pocket of Pk25. The designed test system can 
be used for the primary selection of ATP-competitive small molecule protein kinase inhibitors. 
KEYWORDS serine/threonine protein kinases, indolylmaleimides, protein kinase inhibitors screening, bacterial test 
system, Streptomyces 
S
erine/threonine protein kinases (STPK) are 
a group of universal regulators of the cellular 
metabolism in eukaryotes [1-3]. They play lead-
ing roles in the regulation of apoptosis, proliferation 
and differentiation, cellular transport, etc. It has been 
shown that kinase malfunction can be associated with 
various human diseases, such as diabetes [4], schizo-
phrenia [5], cardiovascular disorders [6,7], and immune 
dysfunctions [8]. Over the past decades, the search for 
new targeted modulators (inhibitors) of protein kinases, 
that are considered as potential drugs, has been inten-
sive [9-11]. 
Eukaryotic type serine/threonine protein kinases 
were found in bacteria, including human pathogens 
[12]. It was shown that STPKs participate in virulence, 
bacterial biofilm formation, tolerance, and persistence 
of pathogenic microorganisms. STPKs were shown 
to play the key role in the virulence of Streptococcus 
pneumonia, Mycobacterium tuberculosis, Staphylococ-
cus aureus, Pseudomonas aeruginosa, and certain other 
pathogens [12-14]. It is  established that STPKs par-
ticipate in the modulation of antibiotic resistance in M. 
tuberculosis [15]. Intensive STPK inhibitors screening is 
currently under way [16-19]. 
We have developed a test system [20] for prescreen-
ing of STPK inhibitors based on the newly constructed 
strain Streptomyces lividans TK24 (66) APHVIII+. The 
key part of this test system is type VIII aminoglycoside 
phosphotransferase (APHVIII), an enzyme that inacti-
vates aminoglycoside antibiotics. Gene aphVIII, which 
is isolated from  Streptomyces rimosus , was cloned into 
S. lividans TK24 (66) and expressed. Importantly, the 
activity of APHVIII S. rimosus is dependent on phos-
phorylation by endogenous STPKs [21]. Phosphoryla-
tion of APHVIII confers Streptomyces cells resistance 
to aminoglycoside antibiotics, while inhibitors of STPK 
render cells more sensitive to aminoglycosides [20]. Al-
teration of the cellular sensitivity to aminoglycoside 
antibiotics in the presence of STPK inhibitors allows 
to perform primary screening of these inhibitors. Upon 
annotation of the genome of the  S. coelicolor A3(2) 
strain (NC_003888), which is close to S. lividans TK24 
Copyright © 2010 Park-media, Ltd. This is an open access article distributed under the Creative  
Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited.RESEARCH ARTICLES
 VOL. 2  № 3 (6)  2010  | ACTA NATURAE | 111
(66) (ACEY01000000), 34 STPKs were identified. At 
least one of them – Pk25 (NCBI Reference Sequence: 
Protein NP_628936.1) – is able to phosphorylate APH-
VIII [22]. In order to rule out a nonspecific action of 
STPK inhibitors on the other STPKs of  S. lividans 
TK24 (66) that are presumably able to phosphorylate 
APHVIII, the catalytic domain of Pk25 kinase and 
APHVIII were hosted in Escherichia coli. The genome 
of E. coli does not contain its own eukaryotic STPKs, 
which makes the test system more sensitive and allows 
the screening of inhibitors that are specific to Pk25 and 
its homologous enzymes [23].
EXPERIMENTAL PROCEDURES
Strains: S. coelicolor A3(2) (Russian Collection of Patho-
genic Microorganisms, Moscow), S. lividans TK24 (66) 
APHVIII+ (GenBank ACEY01000000), E. coli DH5α: 
F-, Ф 80 ΔlacZΔM15, Δ(lacZYA-argF), U169 (Promega); 
BL21(DE3): F-, dcm, ompT, hsdS(rB
-mB
-), galλ(DE3) 
(Novagen).
Plasmids: pET16b, pET22b and pET32а (Novagen). 
Media: S. coelicolor A3(2) and S. lividans TK24 (66) 
APHVIII+ strains were grown on YSP and YEME me-
dia [24]. E.coli strains were grown on Luria broth (L-
broth), NZCYM, M9 supplemented with 1.5 % glycerol 
(1 L): 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g NH4Cl, 
рН 7.4, 2 mL 1 М MgSO4, 15 mL glycerol. Ampicillin 
(100 μg/ml) was added to the media to ensure the sur-
vival of plasmid-containing cells. Protein expression 
was induced by IPTG (1 mM). 
Molecular cloning: Total DNA was isolated from S. 
coelicolor A3(2) and S. lividans TK24 (66) APHVIII+ 
strains according to [24]. Isolation of plasmid DNA, 
preparation of competent E.coli cells, transformation 
and analysis of recombinant plasmids was performed 
according to standard protocols [25]. DNA amplifica-
tion by PCR was carried out by the “Amplification” 
kit (Dialat Ltd.) on the Tertsik TP4-PCR01 amplifica-
tor (DNA-tekhnologiya). The temperature cycle was 
designed according to primer length and composition. 
Oligonucleotides were purchased from Syntol (see Ta-
ble 1). The DNA sequence was determined according 
to Sanger. Nucleotide sequences were compared with 
BLAST (http://www.ncbi. nlm.nih.gov/blast).
Protein electrophoresis was carried out in 12% poly-
acrylamide gels under denaturing conditions, as de-
scribed earlier [21]. Bacterial cells containing construct-
ed plasmids were grown on a NZCYM liquid medium 
supplemented with ampicillin (150 μg/ml) at 34oC up 
to an optical density equal to 0.6 (~1,5 h). Expression of 
the Pk25 catalytic domain was induced by the addition 
of IPTG (final concentration 1 mM). Cells were grown 
at 28oC for 4 h, harvested and re-suspended in a buffer 
containing 62.5 mМ TrisHCl, pH 6.8; 5% glycerol; 2% 
β-mercaptoethanol; 0.1% SDS; and Bromophenol Blue. 
Cells were lysed by boiling for 10 min in the above-
mentioned buffer and subjected to electrophoresis in 
polyacrylamide gels. Approximately 25 μg of the pro-
tein was loaded into each well in the gel. Electrophore-
grams were scanned by laser densitometer Ultroscan 
2205 LKB. A protein fraction of E.coli BL21(DE3) cells 
transfected with the empty vector was used as control.
Isolation of the catalytic domain of Pk25 cloned into 
E.coli cells. Cells were destroyed by sonication in a buf-
fer containing 20 mМ TrisHCl, рН 7.8, 10 mМ 2-mer- М TrisHCl, рН 7.8, 10 mМ 2-mer-  TrisHCl, рН 7.8, 10 mМ 2-mer- рН 7.8, 10 mМ 2-mer-  7.8, 10 mМ 2-mer- М 2-mer-  2-mer-
captoethanol, 300 mМ NaCl, and 1 mM PMSF, or in the 
same buffer supplemented with 8 M urea. Cell debris 
and other undissolved material was removed by cen-
trifugation at 20,000g in 20 min. Fractions of soluble 
proteins were loaded onto a Ni-NTA agarose column 
(Qiagen) which was washed by the above-described 
buffer containing 50 mM imidazole pH 6.0. The protein 
was eluted by the buffer with imidazole concentration 
increasing from 0.05 M up to 0.5 M [20]. Protein frac-
tions were analyzed by SDS-PAGE.
Analysis of autophosphorylation of isolated protein 
by catalytic domain of Pk25 in situ was performed af-
ter separation of the protein under denaturing condi-
tions. Re-naturation of the kinase in gel was carried out 
according to Kashemita and Fujisawa [26]. Gels con-
taining the protein were intensively washed in 50 mМ 
TrisHCl, pH 7.8, with 25% 2-propanol and 8 М urea in 
order to remove SDS. Following that, protein re-na-
turation was carried out by washing gels in buffer A: 
50 mМ TrisHCl, pH 7.8 and B: 50 mМ TrisHCl, pH 7.8, 
100 mМ NaCl, 6 mМ β-mercaptoethanol, 5 mМ MgCl2, 
and 1 mМ CaCl2. After re-naturation, the gels were in-
cubated in the presence of 50 μCi/ml [γ-32P]ATP (7000 
Ci/mM, Phosphor, Russian Federation) in the buffer 
for the analysis of kinase activity [21]. The gels were 
fixed and stained in 40% TCA, washed in 5% acetic acid, 
dried and autoradiographed by exposure to a Kodak 
X-Omat AR film. 
Cloning into expressional vectors pET32a, pET22b, 
and pET16b. Gene pk25 of the S. coelicolor A3(2) strain 
and the gene of S. lividans ТК24 (66) were cloned into 
E.coli in pET32a plasmid at EcoRI and HindIII (primers 
Pk25EN and Pk25C) (Table 1). The gene of the cata-
lytic domain of pk25 of the S. coelicolor A3(2) strain 
was cloned into E.coli in pET22b plasmid at NdeI and 
HindIII (primers Pk25CN and Pk25CC). The modified 
gene aphVII was cloned into E.coli in pET16b plasmid 
at NdeI and XhoI (primers AphN and AphC). The gene 
of the catalytic domain of pk25 of the S. coelicolor A3(2) 
strain was cloned into E.coli in pET16b + aphVIII146-S 
with the non-modified phosphorylation site of APH-
VIII, pET16b + aphVIII146-1, pET16b + aphVIII146-2, 
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rylation sites at the BamHI (primers Pk25NBgl and 
Pk25СBgl).
Cloning of the nucleotide sequence of the pk25 cata-
lytic domain was performed in the рЕТ22b vector at 
NdeI–HindIII restriction sites (primer Pk25CN homol-
ogous to the N-terminal region of the catalytic domain, 
and primer Pk25CC homologous to the C-terminal re-
gion of the catalytic domain). The DNA sequence of 
the catalytic domain was amplified using total DNA 
of S. coelicolor as a template. The PCR product was 
purified from the agarose gel, then sequenced and 
cloned into the рЕТ22b vector at the NdeI and HindIII. 
E. coli DH5a cells were transformed by the resulting 
ligase mix, and screening of recombinant clones was 
carried out by PCR using standard primers T7prom 
and T7term. Plasmid DNA was isolated from selected 
transformants, and the obtained recombinant plasmids 
were sequenced and subjected to restriction analysis 
to verify the presence of the insert. Then, the plasmids 
were used for the transformation of E. coli BL21 (DE3) 
cells.
Site-directed mutagenesis of Ser146 in aminogly-
coside phosphotransferase APHVIII was carried out 
according to Nelson [27]. In order to obtain the mu -
tant variant 1 (amino acid substitutions Ser146Thr, 
Glu144Thr, Asp148Ser), the primers APH 146-1(+) 
and APH 146-1(-) (Table 1) were used. The primers 
APH146-2(+) and APH146-2(-) were used to obtain the 
mutant variant 2 (Glu144Thr, Asp148Ser, Glu150S-
er). The mutant variant 3 represents substitution 
Ser146Thr, which was introduced using the APH146-
T(+) and APH146-T(-)primers.
AphN and AphC corresponding to the 5’- and 3’-ter-
minal fragments of the aphVIII gene were used as 
flanking primers.
The obtained mutant PCR fragments were se -
quenced to verify the nucleotide substitutions and 
cloned at the NdeI and BamHI restriction sites into 
the high-copy number plasmid рЕТ16b containing T7 
phage transcriptional and translational regulatory ele-
ments in the same reading frame with the ATG codone 
of the gene of interest. This plasmid was used for the 
transformation of E. coli DH5a cells, and screening of 
the recombinant clones was carried out by PCR us-
ing T7prom and T7term primers. The selected trans-
formants were used for purification of plasmid DNA, 
which was re-sequenced to ensure the substitutions. 
Determination of resistance to kanamycin in se-
lected transformants of E. coli BL21(DE3). E. coli 
BL21(DE3) clones containing genes of either native or 
modified aphVIII or aphVIII and рk25 in the pET16b 
vector were used for the analysis. The clones resistant 
to ampicillin (100 μg/ml) were transferred on the plates 
with the LB-medium containing various concentrations 
Table 1. Primers which were used in the present work*
Primer Restriction 
site Primer structure, 5’–3’
Pk25EN EcoRI ATCCGAATTATGGCACGGAAGATCGGCAG
Pk25C HindIII CCGCAAGCTTGGTGCCGTTGCCGGAACCG
Pk25CN NdeI TCGTCATATGCGTTACCGGCTCCATGAGCGGC
Pk25CC HindIII CCGCAAGCTTCATCCGCTGGGCCGACGCCG
Pk25NBgl Bgl II TTTTAGATCTAATAAGGAGATATACATGTACCGGCTCCATGAGCGGCT
                                 RBS                                      beginning of pk25 catalytic domain
Pk25СBgl Bgl II CCG CAG ATC TAT CCG CTG GGC CGA CGC CGC 
T7prom — TTAATACGACTCACTATAGG
T7term — CTAGTTATTGCTCAGCGG
APH 146-1(+)   — GCTGTCGCTACAGGGACGGTCAGCTTGGAGGATCTGGAC
APH 146-1(-) — GTCCAGATCCTCCAAGCTGACCGTCCCTGTAGCGACAGC
APH 146-2(+) — GCTGTCGCTACAGGGAGCGTCACCTTGTCGGATCTGGACGAG
APH 146-2(-)   — CTCGTCCAGATCCGACAAGGTGACGCTCCCTGTAGCGACAGC
APH 146-T(+)   — GTCGCTGAAGGGACCGTCGACTTGGAG
APH 146-T(-)   — CTCCAAGTCGACGGTCCCTTCAGCGAC
AphN NdeI TTTTCATATGGACGATGCGTTGCGTGC
AphC BamHI TTTTGGATCCTCAGAAGAACTCGTCCAAC
**Restriction sites are given in bold, nucleotide substitutions are underlined.RESEARCH ARTICLES
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of aminoglycoside antibiotic kanamycin and IPTG as 
the inductor. The growth of colonies was monitored af-
ter 25 hours of incubation at 37°С.
Determination of activity of protein kinase inhibi-
tors in the bacterial test system. Inhibitor activity was 
determined using paper discs. The paper discs soaked 
with antibiotic or an antibiotic/inhibitor mixture were 
placed on the surface of agar plates, and  the size of the 
zone of bacterial growth suppression was measured. 
Test system: E. coli BL21(DE3)APHVIII/�k25. Bacte- BL21(DE3)APHVIII/�k25. Bacte- �k25. Bacte- k25. Bacte-
ria grown on agar plates supplemented with ampicillin 
were washed off into a liquid LB-medium and grown 
overnight at 37оС. Then the cells were pelleted (4,000 
rpm, 10 min) and re-suspended in a liquid M9 medium. 
Bacterial suspension was mixed up in a 1:1 ratio with 
a melted M9-agar medium containing ampicillin and 
IPTG as the inductor. The mixture was poured onto 
Petri dishes with a M9-agar medium containing ampi-
cillin and IPTG. Ampicillin is necessary for maintaining 
the plasmid in the E.coli cells. Paper discs containing 
kanamycin or kanamycin plus the kinase inhibitor were 
placed on the surface of the agar plates and incubated 
for 16 hours at 37оС.
Modeling of Pk25 catalytic domain structure. X-
ray structures of kinase from M. tuberculosis PknB 
(PDB entries PDB [28]: 1MRU [29], 1O6Y [30], 2FUM 
[31], 3F61 [32], 3F69 [32]) were used as templates for 
the model building. Amino acid sequences of the tem-
plate protein were extracted directly from structural 
files; the sequence of S. coelicolor A3(2) was taken from   
GenBank (access code 21223157 [33]). The catalytic do-
main was annotated according to homology. Alignment 
of amino acid sequences was carried out using the Clus-
talX 2.0.11 [34] software. The modeling was performed 
with the Modeller 9v5 [35] program. Thirty-five mod-
els of the catalytic domain were generated, and each 
of them was optimized by simulated annealing. The 
best model was selected according to the DOPE scoring 
function (Modeller software) and  PROCHECK valida-
tion score [36]. Further optimization was performed in 
SYBYL 8.0 [37]; all hydrogen atoms were added to the 
models, and the energy was minimized in the Tripos 
force field [38] by the Powell method.
Modeling of the APHVIII catalytic domain structure 
was based on the X-ray structure of its closest homo-
logue APH(3’)-IIa (PDB entry 1ND4 [39], 36% identity 
of amino acid sequence) in complex with kanamycin. 
The modeling method is similar to the one described 
above: the only difference was that 50 models were 
generated in each case.
Docking of inhibitors into the  Pk25 model was per-
formed using the Autodock 4.1 [40] software. The struc-
tures of the inhibitors were drawn by SYBYL 8.0 and 
optimized with the MMFF94 force field [41]. Docking 
preparation was carried out in MGLTools 1.5.4 [42] ac-
cording to standard recommendations. Generation of 
the grids and docking were performed using default 
parameters, while the position of the docking grid was 
chosen to include all essential amino acid residues of the 
ATP-binding site. During docking of each ligand, 100 
runs of the genetic algorithm were performed. Dock-
ing results were grouped into clusters using a threshold 
value of RMSD  equal to 2.0 Å. The results were analyzed in 
MGLTools 1.5.4.
RESULTS
Cloning and comparison of full-size genes of serine/
threonine protein kinase pK25 from S. coelicolor and 
pK25 S. lividans.
According to genome sequencing data, the gene of the 
pk25 kinase from S. lividans TK24 (ACEY01000000) and 
the gene of pK25 kinase from S. coelicolor share 99.8% 
homology and differ only in 6 base pairs, including an 
insertion of C at position 664. The presence of this inser-
tion leads to the shift of the reading frame in the cata-
lytic domain sequence. In order to compare the kinases 
of interest from our collection of S. coelicolor A3(2) and 
S. lividans TK24 (66) strains, we cloned and sequenced 
the genes of these kinases. To isolate pK25 kinase genes 
from the genomes of S. coelicolor and S. lividans, two 
oligonucleotides containing HindIII and EcoRI were syn-
thesized (pK25EN, homologous to the N-terminal part of 
the gene; and Pk25C, complementary to the C-terminal 
part of the gene, Table 1). Amplification from total DNA 
of S. coelicolor and S. lividans yielded the needed DNA 
fragments, which were cloned into the pET32a vector 
at the HindIII and EcoRI and introduced into  E. coli 
DH5a cells. Sequencing verified that the obtained DNA 
fragments contained the pK25 gene. Comparison of the 
genes from S. coelicolor and S. lividans revealed nucle-
otide substitutions at positions 123, 237, 279, 435, and 963 
starting from the first ATG of the structural region of 
the S. lividans pK25 gene. These nucleotide substitutions 
do not lead to amino acid substitutions in the correspond-
ing proteins. Therefore, the amino acid sequences of the 
full-size pK25 genes from S. coelicolor and S. lividans 
were shown to be identical.
Cloning and expression of the S. coelicolor Pk25 cata-
lytic domain nucleotide sequence into pET22b vector. 
Two oligonucleotides (Pk25CN and Pk25CC) containing 
NdeI and HindIII were synthesized for the cloning (Ta-
ble 1). The fragment obtained during amplification was 
digested with the relevant restriction endonucleases 
and cloned into the pET22b vector that was introduced 
into E. coli DH5a cells. After resequencing, the obtained 
vectors were introduced into the  E. coli BL21(DE3) 
strain used for protein overexpression. 114 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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In order to study the expression of the catalyti -
cal domain of Pk25 kinase in E.coli cells, we set up gel 
electrophoresis of a fraction of soluble cellular proteins 
under denaturing conditions. A protein fraction from 
E. coli BL21(DE3) transformed with an empty pET22b 
vector were used as a control. Electrophoresis showed 
that E.coli cells transformed with the plasmid carry-
ing the gene of the pk25 catalytic domain containing an 
additional protein fraction of 28 kDa (Fig 1a) as com-
pared with the control cells. This value coincides with 
the calculated molecular weight (27.8 kDa) of the cata-
lytic domain of Pk25 kinase from the S. coelicolor A3(2) 
strain. Scanning revealed that the additional fraction 
represents about 3.5% of the total cellular protein.
Modeling of the Pk25 catalytic domain 3D structure.
The key structural features of Pk25 are revealed by the 
model, which is very close to the structure of the tem-
plate protein PknB M. tuberculosis due to the close simi-
larity of the sequences (Fig. 2a). The net charge of the 
catalytic domain is equal to -3. The most obvious differ-
ences between the model and the template are observed 
in the region of helix C (an insertion of four amino acid 
residues in Pk25), in the loop between fragments β4 and 
β5 (deletion of four amino acid residues in Pk25), and 
in the region of the η3 helix (deletion of five amino acid 
residues in Pk25). Conformation of the activation loop 
differs from that in the template due to its flexibility. 
However, the mentioned differences do not affect the 
orientation of amino acid residues in the ATP-binding 
site. There are five amino acid residues in the ATP-bind-
ing pocket of Pk25 that differ from the corresponding 
residues of PknB (Fig. 2b): Val72Ile, Ile90Met, Tyr94Leu, 
Met145Leu, and Met155Thr (numeration of the PknB 
sequence is used). The former three substitutions are 
relatively conserved and should not seriously affect the 
interaction with the inhibitor. Substitution Tyr94Leu is 
located in the hinge region, so ligands interact with the 
backbone of this residue but not with its sidechain. The 
latter two substitutions are not conservative and, there-
fore, should influence the interaction with the inhibitor. 
In particular, these substitutions increase the accessible 
volume of the binding pocket. Finally, an additional hy-
droxy group appears in this region due to the introduc-
tion of a threonine residue at position 155. 
Analysis of autophosphorylation of the Pk25 activa-
tion loop.
A protein fraction of the Pk25 catalytic domain was iso-
lated from lysed E.coli cells by means of chromatography 
on a His-binding resin under either native conditions or 
in the presence of 8M urea. After electrophoresis, we 
were able to analyze its intracellular localization and au-
tophosphorylation in situ. The catalytic domain of Pk25 
was absent in the fraction of salt-soluble cellular pro-
teins. This recombinant protein is present in the frac-
tion of insoluble cellular proteins and can be dissolved in 
the presence of urea, as was done. After separation by 
electrophoresis, the molecular mass of the studied frag-
ment was determined as equal to 28 kDa, which is very 
close to the calculated value. In the presence of [γ-32�]
АТP, the protein accumulates labeled phosphate (Fig. 
1b). Separation of the protein components by gel electro-
phoresis excludes any possible interfering influences of 
other proteins. Over all, the obtained data indicate that 
the isolated catalytic domain of Pk25 kinase is an enzy-
28 kDа*
а  b
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Fig 1. a – Electrophoresis 
of soluble protein fraction 
of E.coli BL21(DE3). 1 – 
marker, 2 – control protein 
fraction of E.coli BL21(DE3) 
рЕТ22b, 3-10 - E.coli 
clones containing рЕТ22b-
рk25. (*- protein fraction of 
Рk25 catalytic domain).
b – Electrophoresis of 
isolated protein fraction of 
S.coelocolor Рk25 catalytic 
domain in PAAG: 1 – auto-
radiogram autophosphori-
late Рk25 catalytic domain, 
2- coloring coomassie 
brilliant blue.RESEARCH ARTICLES
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matically active protein and undergoes autophosphory-
lation. Localization of the Pk25 catalytic domain in the 
fraction of insoluble cellular proteins does not contradict 
the possibility of its autophosphorylation during expres-
sion and, likewise, does not exclude its activity towards 
both soluble and insoluble proteins. These results are in 
agreement with the data obtained on the catalytic do-
mains of Streptomyces and Mycobacterium protein ki-
nases [43-45]. It was shown that phosphorylation in the 
activation loop of STPK occurs at a Ser residue. Analysis 
of the substrate specificity of STPK from M. tuberculosis 
showed that the highest phosphorylation efficiency was 
observed at the regions that are similar to the autophos-
phorylation sites of the kinase [46].
Modeling of the aminoglycoside phosphotransferase 
VIII 3D structure
The model of the APHVIII catalytic domain structure 
closely resembles the template protein APH(3’)-IIa (Fig. 
3a). The two structures are most similar in the sites of 
the ATP and kanamycin binding, as well as in the ac-
tivation loop. The small insertions  in the APHVIII se-
quence are located in the structurally nonconserved re-
gions of the loops, and between various elements of the 
secondary structure they are unlikely to seriously af-
fect the 3D pattern of the polypeptide chain. The physi-
co-chemical properties and conformations of the crucial 
amino acid residues that form the ATP and kanamycin 
binding sites also correspond within the template and 
а b c
а б
Fig 2. The model of Pk25 3D structure. а – Superimposition of the template structure РknB M. tuberculosis (green) and 
Pk25 model (colored by secondary structure type). b – ATP-binding pockets of PknB (colored by atom type) and Pk25 
(orange); nonconservative amino acid residues are shown as sticks. c – binding mode of LCTA-1425 with Pk25. The kinase 
VdW surface is colored according to hydrogen bond donor/acceptor properties (red — donor, blue — acceptor). 
Fig 3. The model 
of APHVIII 3D 
structure. а – 
Superimposition 
of the template 
structure APH(3’)-
IIa (PDB ID 1ND4, 
orange) and 
APHVIII model 
(colored by sec-
ondary structure 
type). b – Amino 
acid residues in 
the activation loop 
of wild-type APH-
VIII (carbons are 
colored orange) 
and 146-1 mutant 
(grey carbons).116 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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the model. The structure of APHVIII146-1 almost fully 
matches that of wild-type protein. Differences are ob-
served in the activation loop and are unlikely to affect 
the global conformation of the protein (Fig. 3b).
The phosphorylation site of APHVII (Ser146) is an 
homologue of phosphoserine in the ribose pocket of 
PKA-type serine/threonine kinases [47]. A molecular 
dynamics simulation of unphosphorylated APHVIII in 
complex with kanamycin (with bound ATP and two 
Mg2+ ions) revealed pronounced alterations of the en-
zyme’s structure, such as weakening of the contact be-
tween the N- and C-terminal domains. [48, 49].
Modification of Ser146 region of aminoglycoside phos-
photransferase APHVII – the site of phosphorylation 
by Pk25 kinase
The autophosphorylation site in the Pk25 activation 
loop was determined through a comparison with the 
corresponding region of M. tuberculosis PknB [50]:
PknB  DFGI  ARAIAD  SGNSVTQTAAVGTAQYLSPE
Pk25  DFGV AQVAGA  TTLTESGSFVGSPEYTAPE
To optimize the test system  E.coli APHVIII/
Pk25, we modified the potential phosphorylation site 
AVAEGS146VDLED in the APHVIII activation loop. 
The objective was to make site Ser146 APHVIII more 
structurally similar to the Pk25 autophosphorylation 
site TTLTESGSFVG. To achieve that, we modified the 
amino acid residues in the vicinity of APHVIII Ser146 
(Table 2), introducing the underlined amino acid sub-
stitutions. The obtained mutant variants of the gene 
aphVIII146-1, aphVIII146-2, aphVIII146-3, and aph-
VIII146-4 were ligated into the pET16b vector at the 
NdeI-BamHI and introduced into E.coli DH5a. After re-
sequencing, the plasmids pET16baphVIIIm1 (Fig. 4a) 
were used for the transformation of E. coli BL21(DE3). 
Expression of all variants of APHVIII in  E.coli was 
checked by gel electrophoresis of soluble cellular pro-
teins under denaturing conditions. 
E.coli cells containing pET16baphVIII plasmid ex-
pressed a 31 kDa protein, which corresponded to the 
calculated molecular mass of APHVIII equal to 31.5 
kDa.
Creation of a construct containing genes of aminogly-
coside phosphotransferase aphVII and protein kinase 
pk25
Amplification of pk25 was performed with the primers 
Pk25NBgl and Pk25СBgl (Table 1) from the DNA of the 
plasmid vector pET22b-pk25. The Pk25NBgl primer 
contained a ribosome-binding site (RBS) and an ATG 
codone for the catalytic domain of protein kinase Pk25. 
The nucleotide sequence of pk25 was amplified and di-
gested by BglII and then ligated into the pET16baph-
VIIIm1 containing the previously described variants 
of aphVIII at the BamHI. At the first stage, the pres-
ence of the insert was checked by amplification with T7 
primers. At the second stage, the clones were selected 
by amplification with AphN and Pk25CC primers (table 
1) according to the presence and the size of the insert. 
After resequencing, pET16APC plasmids (Fig. 4b) were 
used for the transformation of E. coli BL21(DE3). Ex-
pression of genes aphVIII and рk25 after induction was 
checked by gel electrophoresis. In the first four vari-
ants (Fig. 5) (lanes 2-5), additional fractions of APH-
VIII are observed. Lane 6 contains an additional frac-
tion of pk25, while lanes 7-10 contain both a 31.5 kDa 
fraction and a 28 kDa fraction, which are APHVIII and 
Pk25, respectively. Mass-spectrometry was used to 
verify the protein fraction on lane 7. It was shown that 
the heavier fraction contains APHVIII (AAY27879.1 
aminoglycoside-O-phosphotransfe  rase VIII). The other 
fraction contains the catalytic domain of �k25 (1100219 
Table 2. Modifications of phosphorylation site Ser-146 in APHVIII
Native enzymes and modified species of APHVIII Phosphorylation sites and their modifications*
�k25 ATTLTESGSFVG
APHVIII AVAEGS146VDLED
APHVIII146-1 AVATGT146 VSLED
APHVIII146-2 AVATGS146 VSLSD
APHVIII146-3 AVAEGT146VDLED
APHVIII146-4 AVAEGA146VDLED
*Amino acid substitutions are underlined.RESEARCH ARTICLES
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NP_628936.1 serine/threonine protein kinase S. coeli-
color A3(2)).
Analysis of kanamycin resistance in E.coli BL21(DE3) 
variants containing different modifications of aphVIII 
and their combinations with pk25.
Resistance of all constructs to  aminoglycoside antibi-
otic kanamycin was studied (Table 3). The BL21(DE3) 
strain containing the plasmid pET16b encoding gene 
aphVIII was resistant to kanamycin (325 μg/ml).
The substitutions contained in the APHVIII146-1 
variant led to a 48% decrease in resistance. In APH-
VIII146-2, resistance underwent a 54% decrease. The 
level of resistance in APHVIII146-3 containing the 
Ser(146)Thr substitution remained unchanged. In the 
case of the Ser(146)Ala substitution (APHVIII146-4), 
which causes the full inactivation of phosphorylation 
at Ser146, a 70% decrease in kanamycin-resistance was 
observed. The level of activity of APHVIII146-4 in vitro 
corresponds to the obtained data - the mutant variants 
exhibited a level of activity equal to 30% of that in wild 
type [51]. All constructs containing APHVIII with �k25 
showed a higher level of activity. We observed a 91% 
increase in kanamycin resistance in the case of APH-
VIII146-1/Pk25, an 83% increase in the case of APH-
VIII146-2/Pk25, and a 23% increase in the case of the 
initial construct APHVIII/Pk25, as well as in that with 
the Ser(146)Thr substitution.
Docking of indolylmaleimide inhibitors into the Pk25 
model
The constructed test system S. lividansAPHVIII+ has 
been used earlier for the screening of various chemical 
substances such as benzodiazines, benzophtalazines, cy-
clopentendions, indolylmaleimides, pyrazoles, thiazoles, 
thiazoltetrazines, etc. (unpublished data). A number of 
indolylmaleimide compounds that exhibit inhibitory ac-
tivity towards protein kinases were identified. In order 
to propose the binding mechanisms of these substances, 
we carried out a molecular docking study. The results 
suggest that the inhibitors selected in the S. lividans 
TK24 (66) APHVIII/STPK test system (LCTA-1385, 
LCTA-1398, LCTA-1425 [20], bis-indolylmaleimide-1 
[52]) can potentially interact with the ATP binding site 
of Pk25.
Docking of these inhibitors into the Pk25 model re-
veals conservative interactions between the maleimide 
ColE1 pBR322 origin
PstI (5778)
bla(Ap) sequence
EcoRI (6526)
HindIII (30)
T7 terminator
BamHI (320)
aphVIII
RBS
Factor Xa
His tag
NcoI (1209)
lac operator
T7 promoter
lac I
pET16baphVIII m1
6527 bp
а
ColE1 pBR322 origin
PstI (6590)
bla(Ap) sequence
EcoRI (7338) HindIII (30)
T7 terminator
BamHI (731)
catPk25
BamHI (1132)
RBS
aphVIII
RBS
Factor Xa
His tag
NcoI (2021)
lac operator
T7 promoter
lac I
pET16APC
7339 bp
b
Fig 4. Vectors: a - pET16baphVIIIm1 containing aphVIII mutant variants: aphVIII146-1, aphVIII146-2, aphVIII 146-3, 
aphVIII146-4 and primary aphVIII146-S. b – pET16APC containing pk25 and aphVIII mutant variants aphVIII146-1, 
aphVIII146-2, aphVIII146-3, and primary aphVIII146-S.
31.5 kDа
28 kDа
1  2  3  4  5  6  7  8  9  10
Fig 5. Electrophoresis of E.coli BL21(DE3) proteins 
including Рk25 catalytic domain, APHVIII: 1 – marker, 2 - 
primary APHVIII146-S fraction, 3 - APHVIII146-1 fraction, 
4 – APHVIII146-2, 5 – APHVIII146-3, 6 – Рk25 catalytic 
domain, 7 – APHVIII146-S /Pk25 fractions, 8 – APH-
VIII146-1/Pk25, 9 – APHVIII146-2/Pk25, 10 – APH-
VIII146-3/Pk25. E.coli BL21 (DE3) pET22b/рk25 and 
E.coli BL21 (DE3) pET16baphVIII protein fractions ana-
lyzed as a negative control.118 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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moiety and the backbone of the kinase (Fig. 2c). The 
inhibitors bis-indolylmaleimide-1 (Bis-I) and LCTA-
1425 form two hydrogen bonds – one between the car-
bonyl oxygen atom of the maleimide moiety and the 
amide hydrogen of Val96, and another one between the 
imide hydrogen atom of the maleimide moiety and the 
carbonyl oxygen of Glu94. Inhibitors LCTA-1385 and 
LCTA-1398 were shown to form only the former hy-
drogen bond, since the hydrogen atom of the maleim-
ide moiety is substituted in their molecules. Therefore, 
the estimated energy of interaction between Pk25 and 
the latter two inhibitors is 1 kcal/mol less than that for 
the first two compounds. However, in both cases the 
interaction between the kinase and inhibitor is consid-
ered favorable.
Choice and validation of E.coli APHVIII/Pk25-based 
test system
Earlier we constructed and validated [20, 53, 54] a test 
system based on S. lividans TK24 (66) APHVIII/STPK 
[20]. The effect registered in this system was based on 
the cumulative action of the antibiotic kanamycin and 
a STPK modulator in a sub-inhibiting concentration 
[20] that resulted in the appearance of or increase in a 
zone of growth inhibition of the indicator culture. The 
size of the no-growth zone allowed to roughly estimate 
the efficiency of the STPK inhibitor [20]. That is why 
the range of changes of the resistance level to kana-
mycin, which is determined by various constructions 
of APHVII, is of crucial importance. Based on this con-
sideration, APHVIII146-1 is more favorable; so, in fur-
Inactive  
Bis-5
Bis-5+  
Kanamycin
Active   
Bis-1
Kanamycin
Bis-1+   
Kanamycin
а b
signal
pk inhibitor Pk25
not phosphorylation
AphVIII Ser146-1, KanS (170 mkg/ml)
Sensitivity to Kanamycin
signal
Pk25 
phosphorylation
AphVIII Ser146-1, KanR (325 mkg/ml)
Resistance to Kanamycin
Table 3. Kanamycin resistance of E. coli BL21(DE3) strain containing various APHVIII species.
Name Modified constructs APHVIII
Kanamycin resistance of E. coli, , μg/ml
APHVIII APHVIII+Pk25
146-S AVAEG S146 VDLED 325±5 400±10
146-1 AVATG T146 VSLED 170±10 325±5
146-2 AVATG S146 VSLSD 150±10 275±10
146-3 AVAEG T146 VDLED 325±5 400±10
146-4 AVAEG А146 VDLED 100±5 -
Fig. 6. Bacterial test-system E. coli aphVIII /Pk25 for screening of inhibitors of serine-threonine protein kinases. a – The 
principle of the test-system: phosphorilation of Ser-146 Pk25 in APHVIII leads to kanamycin-resistance in E.coli; ad-
dition of inhibitor prevents phosphorylation and reduces kanamycin resistance. b – Validation of the test-system with 
application of Bis-1 and Bis-5 as classical inhibitors [52]: addition of Bis-1 leads to the increase in the zone’s size.RESEARCH ARTICLES
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ther studies we used E.coli APHVIII146-1/Pk25 cells. 
For test system validation, we employed the previously 
described indolylmaleimide STPK inhibitors LCTA-
1385, LCTA-1398, LCTA-1425 [20], and Bis-1 [52] (Ta-
ble 4). The standard concentration of kanamycin was 
5 mg/disc, causing the appearance of a 10-mm zone of 
growth inhibition. All investigated compounds lowered 
kanamycin resistance. Substances from the indolylma-
leimide library (LCTA-1033, LCTA-1196, Bis-5) that 
did not exhibit inhibitory activity in S. lividans TK24 
(66) APHVIII/STPK [20] showed no effect in the E. coli 
APHVIII146-1/�k25-based test system that confirms 
the relevance of the latter. 
DISCUSSION
Perspectives of application of E. coli APHVIII146-1/
Рk25-based test system in screening for STP� inhibi- k25-based test system in screening for STP� inhibi-
tors
The proposed test system can be used in prescreening 
for ATP-competitive low molecular weight inhibitors 
[2] that are able to diffuse in an agar-based medium, 
permeate through the E.coli cell wall, and interact with 
the adenine binding site of Pk25. The selectivity of the 
inhibitors depends on their affinity to  adenine binding 
pocket of the kinase. IFunctional similarity of the amino 
acid sequences leads to the similarity of the three-di-
mensional structures. This is also applicable in the case 
of the ligand binding sites that are responsible for the 
selectivity of inhibitors [55, 56].
The alignment of the amino acid sequence of the 
Pk25 catalytic domain with the catalytic domains of 
other bacterial STPKs, including those from patho-
genic microorganisms performed in Genomic BLAST 
(http://www.ncbi.nlm.nih.gov/sutils/genom_table.
cgi), revealed 13 proteins that share more than 35% 
identity. Among them are STPKs from Mycobacteri-
um, Staphylococcus, Streptococcus, and Pseudomonas. 
Comparison of Pk25 with human STPKs revealed 19 
proteins with more than 30% identity, including kinas-
es from the SAD, BR, NUAK (SNF), DAPK3, PNCK, 
CAMKII, CAMKI, Zip, PKA, HUNK, PAK2, Mark-
PAR1, SIK2, and OPK NimA families.
STPK inhibitors compete with ATP for the binding 
site and interact with the adenine binding pocket of the 
ATP binding site, which contains conservative and vari-
able amino acid residues. We classified STPKs of gram-
positive bacteria [23, 57] based on the physico-chemical 
properties of the sidechains of 9 variable amino acids in 
Table 4. Dependence of E. coli APHVIII146-1/Рk25 kanamycin resistance on various STPK inhibitors.
Known indolylmaleimide 
inhibitors of STPKs. Structure Subinhibiting  
concentration, nmol/disc
Inhibition zone in  
E. coli APHVIII146-1/�k25 test-system In 
the presence of kanamycin and inhibitor, mm
Bis-1 700 13.0
LCTA-1425 125 12.0
LCTA-1398 250 13.0
LCTA-1385 125 12.0
Note. Kanamycin-caused inhibition (5 mg/disc) zone size is 10 мм. Kanamycin resistance of E. coli strain containing 
APHVIII146-1 and Рk25 was determined by means of the paper disc method as described in “Experimental procedures”. 
Indolylmaleimides of LCTA series, provided by Prof. M.N. Preobrazhenskaya, were described earlier [20].120 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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Table 5. Ligand-binding amino acid residues of adenine-binding pocket of bacterial and human serine-threonine protein 
kinases.
Protein kinase Functions of kinases in pathogenesis 
and physiology
Amino acids of the 
binding pocket
Effect  
of substitution
Bacterial STPKs
Pk25 S. coelicolor Modulation of resistance of aph-gene   L V  A  V  M  L  V L  T Original
PknA M. tuberculosis Synthesis of cell wall   I V  A I M  L V L  T Non-essential
PknJ M. tuberculosis Persistence in the host   L V  A I M  F V L  S »
Stk1 Streptococcus agalactiae Gerulation of intracellular segregation of 
GBS and virulence   I V  A I M  Y  V L  T »
StkP S. pneumonia A fragment of signal pathway involved in 
lung and blood invasion   I V  A I M  Y  V L  T »
SP-STK  S. pyogenes Cell division, colony morphology, virulence   I V  A I M  Y  V L  T »
PpkA P. aeruginosa Regulation of expression of virulence factors   L V  A T  M   Y  L L  S Essential
PknB/Stk1 Staphylococcus 
aureus subsp. aureus
Regulation of purine biosynthesis, autolysis, 
core metabolism pathways   L V  A I M  Y I L  F »
PknB  M.  tuberculosis Cell division, inhibition of lysosome fusion   L V  A I M  Y  V   M  M »
Homo sapiens STPK
�КА H. sapiens Allergy, myocardial disorders   L V  A L  M   Y  V L  T Non-essential
CaMK ID H. sapiens Type II diabetes   L V  A I M  L V L  S »
Pac2 H. sapiens UV-caused epidermis diseases   I V  A I M  Y  L L  T »
BR kin1 H. sapiens Regulation of cellular homeostasis   L  VA V L H  V L  A Essential
NUAK SNF1-l1 H. sapiens Modulation of TNF-alpha in cancer cells   L V  A I M  Y  A L  A »
CaMКII H. sapiens Induction of long-termed synaptic memory   L V  A I M  Y  A L  A »
Note. Table represents serinen-threonine kinases containing no more than four amino acid substitutions in ligand-binding 
sequence LVAVMLVLT Рk25. Non-essential amino-acid substitutions are marked (–), while essential substitutions are 
marked (=), substitutions in the gatekeeper region are marked (   ). Selectivity of inhibitors is determined by their affinity 
to the 9 amino acid motifs of the adenin-binding pocket of STPKs.
the adenine binding pocket of the catalytic domain. In 
this work, we used this classification to select STPKs of 
pathogenic bacteria that can be inhibited by the com-
pounds selected in the proposed E. coli APHVIII/�k25 
test system. Table 5 contains 9 of the 13 potential ligand 
binding motifs of STPKs from pathogenic bacteria and 
6 of the 19 motifs of human STPKs. The selection was 
based on the presence of no more than 4 out of 9 ami-
no acid substitutions in variable positions of the ade-
nine-binding pocket of Pk25 S. lividans (S. coelicolor) 
LVAVMLVLT. Substitutions of nonpolar amino acids by 
polar ones at the first four positions, as well as in position 
8 (double underlined), were considered essential. All sub-
stitutions (except for the introduction of a similar amino 
acid) in position 9 (double underlined), and any substi-
tutions in position 5 gatekeeper (underlined), were also 
considered essential. Substitutions in the hinge region 
(position 7 and in position 6) are less essential. Nonessen-
tial substitutions were underlined. The presence of two 
out of four nonessential substitutions does not alter the   
interaction mode of inhibitors with the adenine binding 
site of the protein kinase. Therefore, Pk25 can serve as a 
tool for the selection of inhibitors for 5 of the 13 STPKs 
from pathogenic bacteria and 3 of the 19 human STPKs. RESEARCH ARTICLES
 VOL. 2  № 3 (6)  2010  | ACTA NATURAE | 121
The principle of structural similarity of the adenine 
binding pockets is a more reliable criterion than homol-
ogy of the sequences of the whole catalytic domain.
In conclusion, the proposed test system can be used 
in prescreening for inhibitors of STPKs from some 
pathogenic microorganisms such as PknA, PknJ from 
M. tuberculosis, StkP from S. pneumonia, SP-STK 
from S. pyogenes, as well as some human STPKs, e.g. 
�КА, СаМkinase1, and Pac2. 
This work was supported by the Russian Foundation 
for Basic Research (grant № 09-04-12025).
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